Amneal Pharmaceuticals, Inc. Class A (AMRX)

Amneal Pharmaceuticals' stock has trended upwards by 37.03% in the past six months. The U.S. commercial launch of Brekiya and the submission of a Biologics License Application (BLA) to the U.S. FDA and acceptance of a Market Authorization Application by the European Medicines Agency for ADL-018 impacted the stock price. Amneal also received U.S. FDA approval for Bimatoprost Ophthalmic Solution, 0.01%, and Sodium Oxybate Oral Solution. Amneal initiated a recall of three lots of its Sulfamethoxazole/Trimethoprim tablets due to reports of black spots. Amneal missed Wall Street's revenue expectations for Q1 CY2025, though sales rose 5.5% year-on-year to $695.4 million, and adjusted EPS beat estimates by 43.2%. The company also launched BORUZU, the first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma. Amneal reported Q4 CY2024 results, beating revenue expectations with sales up 18.4% year-on-year to $730.5 million, but adjusted EPS missed estimates. The company also announced BLA submissions for two Denosumab biosimilars were accepted for review by the U.S. FDA.

Amneal Pharmaceuticals typically experiences its lowest revenue quarter in the first quarter of each year, consistent with trends in the U.S. pharmaceutical industry. Demand for certain products is affected by seasonality, such as oseltamivir sales correlating with flu seasonality and Adrenaclick sales correlating with allergy seasonality.

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing, manufacturing, marketing, and distributing essential medicines. It operates in the healthcare sector, specifically in the drug manufacturers - specialty & generic industry, and is structured into three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers a range of generic dosage forms and delivery systems. The Specialty segment focuses on proprietary branded pharmaceuticals for central nervous system and endocrine disorders, including products like Rytary, Unithroid, ONGENTYS, CREXONT, and Brekiya. The AvKARE segment distributes pharmaceuticals, medical, and surgical products and services, primarily to U.S. governmental agencies.

Amneal Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey, United States, and has a global presence with operations in the U.S., India, and Ireland. Its manufacturing plants are located in New Jersey, New York, India, and Ireland, with distribution and commercial operations in Glasgow, Kentucky.

Amneal Pharmaceuticals' brand reputation has been influenced by positive product developments and a product recall. The launch of Brekiya and FDA approvals for new products and biosimilars contribute positively to its reputation. However, the recall of Sulfamethoxazole/Trimethoprim tablets due to microbial contamination negatively impacted the company's brand reputation.

Amneal Pharmaceuticals is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold approximately 45.05% of the company, while Amneal Pharmaceuticals insiders own about 118.59%. Retail investors hold 0.00% according to one source, while another indicates approximately 38.16% of the stock is held by retail investors. Major institutional owners include Vanguard Group Inc, Tpg Gp A, Llc, and BlackRock, Inc. Tushar Bhikhubhai Patel is the largest shareholder, owning 155.73 million shares, representing 49.58% of the company.